| 1 |
Abiodun OE, Adebimpe O, Ndako JA, Oludoun O, Aladeitan B, Adeniyi M. Mathematical modeling of HIV-HCV co-infection model: Impact of parameters on reproduction number. F1000Res 2022;11:1153. [PMID: 36636470 DOI: 10.12688/f1000research.124555.2] [Reference Citation Analysis]
|
| 2 |
Abiodun OE, Adebimpe O, Ndako JA, Oludoun O, Aladeitan B, Adeniyi M. Mathematical modeling of HIV-HCV co-infection model: Impact of parameters on reproduction number. F1000Res 2022;11:1153. [PMID: 36636470 DOI: 10.12688/f1000research.124555.2] [Reference Citation Analysis]
|
| 3 |
Martínez-Román P, Crespo-Bermejo C, Valle-Millares D, Lara-Aguilar V, Arca-Lafuente S, Martín-Carbonero L, Ryan P, de Los Santos I, López-Huertas MR, Palladino C, Muñoz-Muñoz M, Fernández-Rodríguez A, Coiras M, Briz V, On Behalf Of The Covihep Network. Dynamics of HIV Reservoir and HIV-1 Viral Splicing in HCV-Exposed Individuals after Elimination with DAAs or Spontaneous Clearance. J Clin Med 2022;11. [PMID: 35806864 DOI: 10.3390/jcm11133579] [Reference Citation Analysis]
|
| 4 |
Shikuma CM, Le T, Phuong TV, Chew GM, Nguyen VVC, Vo TL, Siriwardhana C, Chow D, Ghukasyan H, Limpruttidham N, Premeaux T, Gangcuangco LM, Paul R, Ndhlovu LC. Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. AIDS Res Hum Retroviruses 2022;38:441-50. [PMID: 34861767 DOI: 10.1089/AID.2021.0076] [Reference Citation Analysis]
|
| 5 |
Álvarez B, Navarrete-Muñoz MA, Briz V, Olmedillas-López S, Nistal S, Cabello A, Prieto L, Górgolas M, García-Arranz M, Benito JM, Rallón N. HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy. Sci Rep 2022;12:5095. [PMID: 35332180 DOI: 10.1038/s41598-022-08871-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Dalla E, Bulfoni M, Cesselli D, Pravisani R, Hidaka M, Eguchi S, Baccarani U. Reinfection of Transplanted Livers in HCV- and HCV/HIV-Infected Patients Is Characterized by a Different MicroRNA Expression Profile. Cells 2022;11:690. [DOI: 10.3390/cells11040690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Brochado-Kith Ó, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Front Immunol 2021;12:723196. [PMID: 34497613 DOI: 10.3389/fimmu.2021.723196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 8 |
Gobran ST, Ancuta P, Shoukry NH. A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. Front Immunol 2021;12:726419. [PMID: 34456931 DOI: 10.3389/fimmu.2021.726419] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 9 |
Sung PS, Shin EC. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. J Clin Med 2021;10:E221. [PMID: 33435135 DOI: 10.3390/jcm10020221] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
